Study of 2.9k offspring exposed to adalimumab, infliximab, golimumab during pregnancy, as compared to etanercept and certolizumab showed an adjusted hazard ratio for serious infections of 1.20 (CI 0.54, 2.64). @RheumNow #EULAR2022 ABST#OP0130

Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis). @RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW

No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest. @RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8

Does MTX have an impact on UST-immunogenicity in PsA? Post-hoc analysis from UST RCT in 110+ pts No difference in ADA rates & concentrations between MTX and non-MTX groups and ADA not associated w/ decreased UST levels POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT

Kimme Hydrich: There is no increased of "exceedingly rare" vaccination adverse effects in rheumatic patients 💉APLS is NOT a risk factor for thrombotic AEs with vaccination #EULAR2022 @Rheumnow @rheum_covid

Ghalandari et al EUDRAVIGILANCE database congenital malformations for non-TNFi bDMARDs (vs certolizumab). ORs suggest possible B-cell modulators and vedolizumab, not others. Geneticist rvw no pattern for B-cell agents. @RheumNow #EULAR2022 OP0129 https://t.co/nrj8MxjAri https://t.co/p6JkfjjtdH

• EULAR Abstract Archive

Proof that MTX doesn't affect sperm! Sperm morphology, motility, concentration, semen volume, testosterone/LH/FSH similar b/f and after exposure; DNA fragmentat'n was⬆️in pre-MTX exposure (possible reason high dz activity contributes to infertility) #EULAR2022 @rheumnow OP0131 https://t.co/JWLEggRhAY